Companies Disc Medicine, Inc.
Disc Medicine (IRON): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Disc Medicine, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers67th pct.Of 18 peer CEOs
CEO pay, last three years
- $903,461FY2023
- $9,065,924FY2024
- $9,986,626FY2025
CEO total pay was $9,986,626 in fiscal 2025, up from $9,065,924 in fiscal 2024.
FY2025: salary $695,000 · bonus $0 · stock awards $4,285,817 · option awards $4,441,046
Executives and directors
Jean Franchi · CFOJohn Quisel · CEOJonathan Yu · COOPamela Stephenson · CCOWilliam Savage · Chief Medical OfficerDonald Nicholson, Ph.D · Chair of the BoardGeorges Gemayel, Ph.D · Independent DirectorJohn Quisel, J.D., Ph.D · DirectorKevin Bitterman, Ph.D · Independent DirectorLiam Ratcliffe, M.D., Ph.D · Independent DirectorMark Chin, M.S., M.B.A · Independent DirectorMona Ashiya, Ph.D · Independent DirectorNadim Ahmed, M.S · Independent DirectorWilliam White, M.P.P., J.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Disc Medicine, Inc. in fiscal 2025?
As disclosed, John Quisel (President and Chief Executive Officer) was the highest-paid executive at Disc Medicine, Inc. in fiscal 2025, with total compensation of $9,986,626.
How does Disc Medicine, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, John Quisel's total compensation ranked at the 67th percentile of Disc Medicine, Inc.'s disclosed peer group.
What is Disc Medicine, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Disc Medicine, Inc.'s CEO-to-median employee pay ratio was 18:1.
How did shareholders vote on Disc Medicine, Inc.'s executive compensation?
As disclosed, 98.91% of shareholders supported Disc Medicine, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Disc Medicine, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Disc Medicine, Inc. reported total board compensation of $513,587 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Quisel | $695,000 | $0 | $4,285,817 | $4,441,046 | $554,263 | $0 | $10,500 | $9,986,626 |
| President and Chief Executive Officer | ||||||||
| Jean Franchi | 531,000 | 0 | 1,969,560 | 1,360,603 | 307,980 | 0 | 0 | 4,169,143 |
| Chief Financial Officer | ||||||||
| Pamela Stephenson | 520,000 | 0 | 1,969,560 | 1,360,603 | 301,600 | 0 | 10,500 | 4,162,263 |
| Chief Commercial Officer | ||||||||
| William Savage | 523,000 | 0 | 1,313,040 | 1,360,603 | 303,340 | 0 | 10,500 | 3,510,483 |
| Chief Medical Officer | ||||||||
| Jonathan Yu | 507,000 | 0 | 1,313,040 | 1,360,603 | 294,060 | 0 | 10,500 | 3,485,203 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Quisel | $9,986,626 | $9,065,924 | $903,461 | ↑ +920,702 |
| Jean Franchi | 4,169,143 | 5,300,150 | — | ↓ −1,131,007 |
| Pamela Stephenson | 4,162,263 | 5,205,054 | — | ↓ −1,042,791 |
| William Savage | 3,510,483 | 3,053,156 | 687,740 | ↑ +457,327 |
| Jonathan Yu | 3,485,203 | 2,936,021 | 628,005 | ↑ +549,182 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We believe that in order to create value for our stockholders, it is critical to attract, motivate and retain key executive officer talent by providing competitive compensation packages that reward our executives for company performance. Accordingly, the objectives of our executive officer compensation program are to: Attract and retain a highly-skilled team of executive officers who have the expertise to successfully execute on our business plans within the highly competitive life sciences industry; Motivate and reward the achievement of performance goals that directly correlate to increasing stockholder value; and Align the interests of our executives with the interests of our stockholders by tying compensation to the achievement of short- and long-term strategic and financial goals and stock price performance.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | False |
| Anti-pledging | False |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| William Savage | RSU | 2025-02-10 | — | — | 24,000 | — | $1,313,040 |
| Pamela Stephenson | RSU | 2025-02-10 | — | — | 36,000 | — | 1,969,560 |
| John Quisel | RSU | 2025-02-10 | — | — | 78,337 | — | 4,285,817 |
| Jean Franchi | RSU | 2025-02-10 | — | — | 36,000 | — | 1,969,560 |
| Jean Franchi | OPTION | 2025-02-10 | — | — | 36,000 | — | 1,360,603 |
| Jonathan Yu | RSU | 2025-02-10 | — | — | 24,000 | — | 1,313,040 |
| Pamela Stephenson | OPTION | 2025-02-10 | — | — | 36,000 | — | 1,360,603 |
| William Savage | OPTION | 2025-02-10 | — | — | 36,000 | — | 1,360,603 |
| John Quisel | OPTION | 2025-02-10 | — | — | 117,505 | — | 4,441,046 |
| Jonathan Yu | OPTION | 2025-02-10 | — | — | 36,000 | — | 1,360,603 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| William Savage | $1,313,040 | $0 | $1,360,603 | 0.0% |
| Pamela Stephenson | 1,969,560 | 0 | 1,360,603 | 0.0% |
| John Quisel | 4,285,817 | 0 | 4,441,046 | 0.0% |
| Jean Franchi | 1,969,560 | 0 | 1,360,603 | 0.0% |
| Jonathan Yu | 1,313,040 | 0 | 1,360,603 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jonathan Yu | Option | 8,462 | 13.5 | — |
| William Savage | Option | 9,731 | 13.5 | — |
| Jonathan Yu | RSU | 13,624 | — | 1,081,882 |
| William Savage | RSU | 13,901 | — | 1,103,878 |
| Jonathan Yu | Option | 14,193 | 63.9 | — |
| William Savage | Option | 14,480 | 63.9 | — |
| William Savage | RSU | 24,000 | — | 1,905,840 |
| Jonathan Yu | RSU | 24,000 | — | 1,905,840 |
| Jean Franchi | RSU | 27,499 | — | 2,183,696 |
| Pamela Stephenson | RSU | 27,499 | — | 2,183,696 |
| Jean Franchi | Option | 28,500 | 54.71 | — |
| Pamela Stephenson | Option | 28,500 | 54.71 | — |
| William Savage | Option | 28,500 | 54.71 | — |
| Jonathan Yu | Option | 28,500 | 54.71 | — |
| Pamela Stephenson | Option | 29,792 | 64.66 | — |
| Jean Franchi | Option | 29,792 | 65.25 | — |
| John Quisel | Option | 33,001 | 13.5 | — |
| Jean Franchi | RSU | 36,000 | — | 2,858,760 |
| Pamela Stephenson | RSU | 36,000 | — | 2,858,760 |
| John Quisel | RSU | 49,774 | — | 3,952,553 |
| John Quisel | Option | 51,849 | 63.9 | — |
| John Quisel | RSU | 78,337 | — | 6,220,741 |
| John Quisel | Option | 93,025 | 54.71 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nadim Ahmed, M.SIndependent | $21,087 | — | $964,522 | — | — | $985,609 |
| Donald Nicholson, Ph.DNot independent · Board Chair · Nominating and Corporate Governance · Compensation (Chair) | 170,000 | — | 418,177 | — | — | 588,177 |
| Georges Gemayel, Ph.DIndependent | 45,000 | — | 468,238 | — | — | 513,238 |
| William White, M.P.P., J.DIndependent · Audit (Chair) · Nominating and Corporate Governance | 60,000 | — | 418,177 | — | — | 478,177 |
| Kevin Bitterman, Ph.DIndependent · Nominating and Corporate Governance (Chair) · Compensation | 57,500 | — | 418,177 | — | — | 475,677 |
| Liam Ratcliffe, M.D., Ph.DIndependent · Nominating and Corporate Governance · Audit · Compensation | 55,000 | — | 418,177 | — | — | 473,177 |
| Mark Chin, M.S., M.B.AIndependent · Audit · Nominating and Corporate Governance | 52,500 | — | 418,177 | — | — | 470,677 |
| Mona Ashiya, Ph.DIndependent | 52,500 | — | 221,872 | — | — | 274,372 |
| John Quisel, J.D., Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $365,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $513,587 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $513,587 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Disc Medicine as a peer
Companies that benchmark against IRON
5 companies name IRON as a compensation peer
- Dianthus Therapeutics, Inc. /DE/DNTHFY2025
- Keros Therapeutics, Inc.KROSFY2025
- PLIANT THERAPEUTICS, INC.PLRXFY2025
- Protagonist Therapeutics, IncPTGXFY2025
- Spyre Therapeutics, Inc.SYREFY2025
Each company listed discloses IRON in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IRON in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
DYN Dyne Therapeutics, Inc.FULC Fulcrum Therapeutics, Inc.STOK Stoke Therapeutics, Inc.ETNB 89Bio, Inc.AKRO Akero Therapeutics, Inc.CNTA Centessa Pharmaceuticals plcCOGT Cogent Biosciences, Inc.CGEM Cullinan Therapeutics, Inc.EWTX Edgewise Therapeutics, Inc.IDYA IDEAYA Biosciences, Inc.ITOS iTeos Therapeutics, Inc.KYMR Kymera Therapeutics, Inc.PTGX Protagonist Therapeutics, Inc.SRRK Scholar Rock Holding CorporationSNDX Syndax Pharmaceuticals, Inc.TERN Terns Pharmaceuticals, Inc.VRDN Viridian Therapeutics, Inc.KROS Keros Therapeutics, Inc.
Peer reciprocity
The companies Disc Medicine, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Cogent Biosciences, Inc. | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | 170,625 | 11,590,000 | 14,035,067 | 0 | 27,031,655 |
| 4 | Protagonist Therapeutics, Inc. | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 5 | Centessa Pharmaceuticals plc | 2025 | Saurabh Saha | 683,884 | 0 | 10,755,360 | 0 | 11,877,244 |
| 6 | Akero Therapeutics, Inc. | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 7 | Disc Medicine, Inc. | 2025 | John Quisel | 695,000 | 4,285,817 | 4,441,046 | 554,263 | 9,986,626 |
| 8 | Ideaya Biosciences, Inc. | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 9 | Kymera Therapeutics, Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 10 | Terns Pharmaceuticals, Inc. | 2024 | Amy Burroughs | 563,701 | 807,750 | 6,476,968 | 375,000 | 8,240,502 |
| 11 | 89Bio, Inc. | 2024 | Rohan Palekar | 646,000 | 1,996,000 | 4,623,592 | 337,535 | 7,619,426 |
| 12 | Edgewise Therapeutics, Inc. | 2025 | Kevin Koch | 670,000 | 1,171,625 | 5,041,621 | 462,300 | 7,359,546 |
| 13 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 14 | Viridian Therapeutics, Inc. | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 15 | iTeos Therapeutics, Inc. | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 16 | Cullinan Therapeutics, Inc. | 2025 | Nadim Ahmed | 698,476 | 1,697,400 | 2,234,340 | 419,086 | 5,100,006 |
| 17 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 18 | Keros Therapeutics, Inc. | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 19 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Disc Medicine, Inc. | 145% | RSU 50 · Options 50 | not disclosed | Pearl Meyer |
| 89Bio, Inc. | 95% | not disclosed | No | Aon |
| Akero Therapeutics, Inc. | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Centessa Pharmaceuticals plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Cogent Biosciences, Inc. | 135% | not disclosed | No | Compensia |
| Cullinan Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Compensia (through June 2025); Pay Governance (since June 2025) |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Edgewise Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Ideaya Biosciences, Inc. | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| iTeos Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford |
| Keros Therapeutics, Inc. | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kymera Therapeutics, Inc. | 125% | not disclosed | No | Alpine Rewards |
| Protagonist Therapeutics, Inc. | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Terns Pharmaceuticals, Inc. | 120% | not disclosed | No | Alpine Rewards |
| Viridian Therapeutics, Inc. | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 33,528,449 | 368,970 | 9,830 | 98.91% | Passed |
| 2025 | 2025-06-11 | 30,801,342 | 235,453 | 6,286 | 99.24% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-18 | 98.91%a |
| 2025 | 2025-06-11 | 99.24%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 18 : 1 |
|---|---|
| CEO total compensation | $9,986,626 |
| Median employee compensation | $570,211 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 11,651 | $69 | $801,102 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 13,351 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | A | 13,351 | 10 | 131,641 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 5,261 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | A | 5,261 | 10 | 51,873 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 6,961 | 70 | 486,699 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Richard White | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 34,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 22,927 | 70 | 1,603,019 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | A | 7,500 | 15 | 110,175 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | A | 34,000 | 10 | 335,240 | Common | Form 4 ↗ |
| Nadim Ahmed | Director | 2026-06-18 | A | 5,176 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Liam Ratcliffe | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 1,551 | 72 | 111,071 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 9,522 | 71 | 673,205 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 1,600 | 71 | 113,161 | Common | Form 4 ↗ |
| Mark Chin | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Georges Gemayel | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 500 | 72 | 35,811 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 5,400 | 70 | 377,688 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-22 | D | 9,700 | 73 | 704,795 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-22 | D | 9,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-22 | A | 9,700 | 14 | 130,950 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-26 | — | 1,151 | — | — | 2 insiders, 2 accrual rows | ||
| Rahul Khara | Chief Legal Officer | 2026-06-26 | D | 851 | 75 | 63,825 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-26 | D | 300 | 73 | 21,750 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-26 | A | 300 | 14 | 4,050 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-26 | A | 851 | 15 | 12,501 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-29 | — | 1,649 | — | — | 1 insider, 1 accrual row | ||
| Rahul Khara | Chief Legal Officer | 2026-06-29 | D | 1,649 | 75 | 123,675 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-29 | A | 1,649 | 15 | 24,224 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-07 | — | 100 | — | — | 1 insider, 1 accrual row | ||
| Jonathan Yu | Chief Operating Officer | 2026-07-07 | D | 100 | 83 | 8,250 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-07-07 | A | 100 | 14 | 1,350 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 7,416 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 6,400 | 76 | 486,733 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 16,896 | 75 | 1,266,303 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 9,704 | 74 | 720,744 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | A | 7,416 | 14 | 100,116 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | A | 25,584 | 10 | 252,258 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 25,584 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-08-06 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-08-06 | D | 5,000 | 80 | 400,000 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-08-06 | A | 5,000 | 15 | 73,450 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-12 | — | 804 | — | — | 1 insider, 1 accrual row | ||
| Jonathan Yu | Chief Operating Officer | 2026-08-12 | D | 804 | 83 | 66,445 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-12 | A | 804 | 14 | 10,854 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | A | 33,000 | 14 | 445,500 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 33,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 8,400 | 78 | 656,091 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 11,888 | 80 | 949,162 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 12,712 | 79 | 1,006,729 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-24 | D | 300 | 83 | 24,760 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-24 | A | 300 | 14 | 4,050 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-24 | — | 300 | — | — | 1 insider, 1 accrual row | ||
| Jonathan Yu | Chief Operating Officer | 2026-08-25 | D | 8,796 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-25 | D | 8,796 | 83 | 731,092 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-25 | A | 8,796 | 14 | 118,746 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-01 | D | 58 | 80 | 4,637 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-01 | D | 70 | 80 | 5,597 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-01 | D | 1 | 80 | 80 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 22,090 | 80 | 1,770,955 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 2 | 81 | 162 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 26,542 | 80 | 2,127,872 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 9 | 81 | 729 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 10 | 81 | 810 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 511 | 80 | 40,967 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-03 | D | 2,339 | 80 | 187,073 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-03 | D | 2,810 | 80 | 224,744 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-03 | D | 54 | 80 | 4,319 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-04 | D | 759 | 80 | 60,690 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-04 | D | 912 | 80 | 72,924 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-04 | D | 18 | 80 | 1,439 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 7,136 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 27,136 | 70 | 1,902,505 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | A | 10,000 | 39 | 388,500 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | A | 7,136 | 46 | 326,044 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | A | 10,000 | 51 | 508,600 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-09-15 | D | 36,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-09-15 | A | 36,000 | 1 | 36,360 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-19 | D | 4,942 | 80 | 395,212 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-19 | D | 5,937 | 80 | 474,782 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-19 | D | 115 | 80 | 9,197 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-20 | D | 2,388 | 80 | 190,921 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-20 | D | 55 | 80 | 4,397 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-20 | D | 2,869 | 80 | 229,377 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-21 | D | 266 | 80 | 21,341 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-21 | D | 11,470 | 80 | 920,238 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-21 | D | 13,783 | 80 | 1,105,810 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 95 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 11,651 | $69 | $801,102 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 13,351 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | A | 13,351 | 10 | 131,641 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 5,261 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | A | 5,261 | 10 | 51,873 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-16 | D | 6,961 | 70 | 486,699 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Richard White | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 34,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 22,927 | 70 | 1,603,019 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | A | 7,500 | 15 | 110,175 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | A | 34,000 | 10 | 335,240 | Common | Form 4 ↗ |
| Nadim Ahmed | Director | 2026-06-18 | A | 5,176 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Donald William Nicholson | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Liam Ratcliffe | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 1,551 | 72 | 111,071 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-06-18 | D | 9,522 | 71 | 673,205 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 1,600 | 71 | 113,161 | Common | Form 4 ↗ |
| Mark Chin | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Georges Gemayel | Director | 2026-06-18 | A | 6,212 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 7,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 500 | 72 | 35,811 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-18 | D | 5,400 | 70 | 377,688 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-22 | D | 9,700 | 73 | 704,795 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-22 | D | 9,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-22 | A | 9,700 | 14 | 130,950 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-26 | D | 851 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-26 | D | 851 | 75 | 63,825 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-26 | D | 300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-26 | D | 300 | 73 | 21,750 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-06-26 | A | 300 | 14 | 4,050 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-26 | A | 851 | 15 | 12,501 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-29 | D | 1,649 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-29 | D | 1,649 | 75 | 123,675 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-06-29 | A | 1,649 | 15 | 24,224 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-07-07 | D | 100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-07-07 | D | 100 | 83 | 8,250 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-07-07 | A | 100 | 14 | 1,350 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 7,416 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 6,400 | 76 | 486,733 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 16,896 | 75 | 1,266,303 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 9,704 | 74 | 720,744 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | A | 7,416 | 14 | 100,116 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | A | 25,584 | 10 | 252,258 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-07-13 | D | 25,584 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-08-06 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-08-06 | D | 5,000 | 80 | 400,000 | Common | Form 4 ↗ |
| Rahul Khara | Chief Legal Officer | 2026-08-06 | A | 5,000 | 15 | 73,450 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-12 | D | 804 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-12 | D | 804 | 83 | 66,445 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-12 | A | 804 | 14 | 10,854 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | A | 33,000 | 14 | 445,500 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 33,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 8,400 | 78 | 656,091 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 11,888 | 80 | 949,162 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-08-17 | D | 12,712 | 79 | 1,006,729 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-24 | D | 300 | 83 | 24,760 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-24 | A | 300 | 14 | 4,050 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-24 | D | 300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-25 | D | 8,796 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-25 | D | 8,796 | 83 | 731,092 | Common | Form 4 ↗ |
| Jonathan Yu | Chief Operating Officer | 2026-08-25 | A | 8,796 | 14 | 118,746 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-01 | D | 58 | 80 | 4,637 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-01 | D | 70 | 80 | 5,597 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-01 | D | 1 | 80 | 80 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 22,090 | 80 | 1,770,955 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 2 | 81 | 162 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 26,542 | 80 | 2,127,872 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 9 | 81 | 729 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 10 | 81 | 810 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-02 | D | 511 | 80 | 40,967 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-03 | D | 2,339 | 80 | 187,073 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-03 | D | 2,810 | 80 | 224,744 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-03 | D | 54 | 80 | 4,319 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-04 | D | 759 | 80 | 60,690 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-04 | D | 912 | 80 | 72,924 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-04 | D | 18 | 80 | 1,439 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 7,136 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | D | 27,136 | 70 | 1,902,505 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | A | 10,000 | 39 | 388,500 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | A | 7,136 | 46 | 326,044 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-09-11 | A | 10,000 | 51 | 508,600 | Common | Form 4 ↗ |
| John Quisel | Director | 2026-09-15 | D | 36,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Quisel | Director | 2026-09-15 | A | 36,000 | 1 | 36,360 | Common | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-19 | D | 4,942 | 80 | 395,212 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-19 | D | 5,937 | 80 | 474,782 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-19 | D | 115 | 80 | 9,197 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-20 | D | 2,388 | 80 | 190,921 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-20 | D | 55 | 80 | 4,397 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-20 | D | 2,869 | 80 | 229,377 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-21 | D | 266 | 80 | 21,341 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-21 | D | 11,470 | 80 | 920,238 | Common, indirect | Form 4 ↗ |
| Kevin Bitterman | Director | 2026-10-21 | D | 13,783 | 80 | 1,105,810 | Common, indirect | Form 4 ↗ |
Sources (146 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Quisel. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table” · page 33. As printed: 9,986,626. View filing ↗
- Section 01, Jean Franchi. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table”. As printed: 4,169,143. View filing ↗
- Section 01, Pamela Stephenson. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table”. As printed: 4,162,263. View filing ↗
- Section 01, William Savage. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table”. As printed: 3,510,483. View filing ↗
- Section 01, Jonathan Yu. DEF 14A, filed 2026-04-28. Section “2025 Summary Compensation Table”. As printed: 3,485,203. View filing ↗
- Section 03, William Savage RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Pamela Stephenson RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Quisel RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jean Franchi RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jean Franchi OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Yu RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Pamela Stephenson OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, William Savage OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Quisel OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Yu OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 18 : 1. View filing ↗
- Section 08, Nadim Ahmed, M.S. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 985,609. View filing ↗
- Section 08, Donald Nicholson, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 588,177. View filing ↗
- Section 08, Georges Gemayel, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 513,238. View filing ↗
- Section 08, William White, M.P.P., J.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 478,177. View filing ↗
- Section 08, Kevin Bitterman, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 475,677. View filing ↗
- Section 08, Liam Ratcliffe, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 473,177. View filing ↗
- Section 08, Mark Chin, M.S., M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 470,677. View filing ↗
- Section 08, Mona Ashiya, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 274,372. View filing ↗
- Section 08, John Quisel, J.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jonathan Yu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Richard White 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nadim Ahmed 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald William Nicholson 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Liam Ratcliffe 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Chin 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Georges Gemayel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rahul Khara 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Yu 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Quisel 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-20. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-20. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-20. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-21. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-21. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Bitterman 2026-10-21. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-24. Item 5.07 · say-on-pay result. As reported: 98.91% (votes for as printed: 33,528,449). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 99.24% (votes for as printed: 30,801,342). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 513,587 + equity 0 + all other 0 = 513,587, summed across the director compensation table rows.
- Scholar Rock Holding Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. View filing ↗
- Cogent Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. View filing ↗
- Stoke Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. View filing ↗
- Protagonist Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics, Inc.'s own proxy. As printed: 12,871,506. View filing ↗
- Centessa Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Centessa Pharmaceuticals plc's own proxy. As printed: 11,877,244. View filing ↗
- Akero Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics, Inc.'s own proxy. As printed: 10,465,855. View filing ↗
- Disc Medicine, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Disc Medicine, Inc.'s own proxy. As printed: 9,986,626. View filing ↗
- Ideaya Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences, Inc.'s own proxy. As printed: 9,512,640. View filing ↗
- Kymera Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics, Inc.'s own proxy. As printed: 8,545,609. View filing ↗
- Terns Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Terns Pharmaceuticals, Inc.'s own proxy. As printed: 8,240,502. View filing ↗
- 89Bio, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-15. CEO total compensation as printed in 89Bio, Inc.'s own proxy. As printed: 7,619,426. View filing ↗
- Edgewise Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Edgewise Therapeutics, Inc.'s own proxy. As printed: 7,359,546. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Viridian Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics, Inc.'s own proxy. As printed: 6,776,249. View filing ↗
- iTeos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics, Inc.'s own proxy. As printed: 6,085,657. View filing ↗
- Cullinan Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cullinan Therapeutics, Inc.'s own proxy. As printed: 5,100,006. View filing ↗
- Fulcrum Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗
- Keros Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics, Inc.'s own proxy. As printed: 2,540,204. View filing ↗
- Dyne Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. View filing ↗
- Section 10a, Protagonist Therapeutics, Inc. reciprocity. DEF 14A. Protagonist Therapeutics, Inc. names Disc Medicine, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Keros Therapeutics, Inc. reciprocity. DEF 14A. Keros Therapeutics, Inc. names Disc Medicine, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗